# AZD7325 Japan Multiple Ascending Dose (MAD) Study

> **NCT00945425** · PHASE1 · TERMINATED · sponsor: **AstraZeneca** · enrollment: 48 (estimated)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** AZD7325
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00945425
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-07
- **Primary completion:** —
- **Final completion:** 2009-11
- **Target enrollment:** 48 (ESTIMATED)
- **Why stopped:** Decided to stop development of this compound globally
- **Last updated:** 2011-02-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00945425

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00945425, "AZD7325 Japan Multiple Ascending Dose (MAD) Study". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00945425. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*